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AbstrAct
Objectives This prospective cohort study sought to 
estimate health system and household costs for episodes 
of diarrhoeal illness in Malawi.
setting Data were collected in two Malawian settings: a 
rural health centre in Chilumba and an urban tertiary care 
hospital in Blantyre.
Participants Children under 5 years of age presenting 
with diarrhoeal disease between 1 January 2013 and 
21 November 2014 were eligible for inclusion. Illnesses 
attributed to other underlying causes were excluded, as 
were illnesses commencing more than 2 weeks prior to 
presentation. Complete data were collected on 514 cases 
at both the time of the initial visit to the participating 
healthcare facility and 6 weeks after discharge.
Primary and secondary outcome measures The 
primary outcome measure was the total cost of an episode 
of illness. Costs to the health system were gathered from 
chart review (drugs and diagnostics) and actual hospital 
expenditure (staff and facility costs). Household costs, 
including lost income, were obtained by interview with the 
parents/guardians of patients.
results Total costs in 2014 US$ for rural inpatient, rural 
outpatient, urban inpatient and urban outpatient were 
$65.33, $8.89, $60.23 and $14.51, respectively (excluding 
lost income). Mean household contributions to these costs 
were 15.8%, 9.8%, 21.3% and 50.6%.
conclusion This study found significant financial burden 
from childhood diarrhoeal disease to the healthcare 
system and to households. The latter face the risk of 
consequent impoverishment, as the study demonstrates 
how the costs of seeking treatment bring the income of 
the majority of families in all income strata below the 
national poverty line in the month of illness.
IntrOductIOn
Diarrhoea is the major cause of childhood 
illness and death. It is responsible for an esti-
mated 9% of all under-five deaths globally,1 
and in Malawi results in at least 3000 under-
five deaths annually.2 Although the rotavirus 
vaccine was introduced in 2012, incidence of 
rotavirus hospitalisation remains high at 123 
per 100 000 infants (60 per 100 000 children 
aged 1 to 4 years), and this pathogen causes 
the largest share of gastroenteritis-related 
deaths, accounting for 25%.3 4 The toll of diar-
rhoeal disease can be mitigated by treatments 
such as oral rehydration solution, zinc and in 
some cases, antibiotics or hospital-based care. 
Vaccines also play an important role in miti-
gating the spread and severity of diarrhoeal 
disease. Rotavirus vaccines, for example, 
have been introduced in many countries, 
including Malawi, where they prevent infec-
tion and severe disease, and have resulted in 
substantial reductions in rotavirus-associated 
illness and death.5 6
In addition to the burden of disease and 
death in children, treatment costs can cause 
significant financial strain to households and 
healthcare systems alike. In order to under-
stand comprehensively the impact of diar-
rhoeal disease and the potential economic 
benefit of vaccines, one must examine the 
actual costs of care incurred by the health-
care system and by households.
Most economic evaluations have relied on 
model-derived cost estimates based on extant, 
retrospective data. Very few studies have 
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Research
strengths and limitations of this study
 ► We collected costs of illness directly from patient 
caregivers and clinic records rather than relying on 
model-derived estimates.
 ► Collection of information on lost income means that 
we were able to provide more holistic measures of 
the effect of illness on household economy.
 ► Only two clinics were sampled, so the conclusions’ 
generalisability to other locations in Malawi is 
uncertain.
 ► Estimates of the contribution of previous visits to 
overall costs are likely to be confounded by selection 
bias, as the most severe patients are likely to have 
been seen before and to have higher costs.
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prospectively collected direct individual patient-level 
costs of diarrhoeal illness at both inpatient and outpatient 
settings.7 Even fewer have collected such data from health 
facilities and households, including direct and indirect 
medical costs and income loss estimates.8 Additionally, 
many studies lack data on household income that would 
permit examination of differential short-term financial 
effects of illness by income level.
In this post hoc analysis of data collected for a cost-ef-
fectiveness analysis,9 we sought to provide insight into 
the cost of treating diarrhoeal disease from the health 
system and societal perspectives in the context of a low-in-
come country where receipt of both doses of the rota-
virus vaccine is near 90%.10 In other low-income settings, 
geographic setting (urban/rural), treatment setting 
(inpatient/outpatient), household income and dura-
tion of illness have consistently demonstrated correlation 
with the economic burden of diarrhoeal disease.7 11 12 We 
sought to explore these factors that drive cost of illness 
in this sub-Saharan, low-income setting, as well as to 
leverage our capture of prior costs to examine the effects 
of multiple sessions of care on cost.
cOntext And methOds
Study area and population
This prospective cohort study was conducted in Malawi, a 
country of approximately 16 million people in southern 
Africa. Its per capita gross national income of US$350 
places it 210 of 216 countries and territories ranked by 
the World Bank.13 Over 80% of its population is rural, 
with much of that population engaged in subsistence 
farming.14
The study was conducted at two sites: Queen Elizabeth 
Central Hospital (QECH), a national referral hospital 
that provides both inpatient and outpatient care, and 
Chilumba Rural Hospital (CRH), which provides outpa-
tient primary care for children under 5 years and accepts 
inpatients, although generally low acuity cases. QECH is 
located in Blantyre, a district of approximately 1.3 million 
in Malawi’s Southern Region. It receives approximately 
90 000 presentations per year, 25 000 of which are admitted 
to the inpatient facility. CRH is located in Karonga, a 
district of approximately 200 000 in the Northern Region. 
Chilumba hosts a demographic surveillance site with a 
population approaching 40 000.15 It sees 7500 outpatients 
per year, of which about 700 are admitted inpatient. Both 
sites provide basic inpatient and outpatient care free of 
charge and were purposively selected to be representa-
tive of the care provided at different levels of the health 
system.9
Inclusion criteria
Eligible participants were children under 5 years of age 
living in Blantyre district or within the demographic 
surveillance population in Chilumba and presenting 
with diarrhoea at either facility during the study period 
(1 January 2013 to 21 November 2014). Illnesses 
attributed to other underlying causes were excluded, as 
were illnesses commencing more than 2 weeks prior to 
presentation. In addition to identifying participants at 
registration/triage, admission logs and electronic records 
(at QECH only) were reviewed for missing cases.
data collection
After identifying each participant and obtaining consent 
from their caregiver, a trained research assistant admin-
istered a standard case report form to the caregiver. 
The questionnaire included demographic informa-
tion, socioeconomic status and the history of the child’s 
illness prior to presentation at the facility, as well as all 
illness-associated costs incurred prior to presenting at the 
facility. Daily review of medical charts was undertaken 
during admission for inpatients to gather information on 
drugs dispensed, and laboratory investigations or proce-
dures performed. All participants’ homes were visited by 
research staff 6 weeks postdischarge to evaluate whether 
any subsequent illness-related costs were incurred by the 
household.
categorisation of expenses
Pretreatment costs included direct medical costs paid by 
the household for care sought prior to the date of the 
index visit, which we defined as the date of an outpa-
tient visit at either facility or the first day of an inpatient 
stay. Since the health facilities at which previous care was 
sought were not study sites, costs to the health system 
were not included in the pre-index costs.
Costs of the index visit were divided into health system 
and household costs. Costs to the health system included 
drugs, laboratory investigations, staff and facility costs 
such as laundry, kitchen, sanitation and security. The cost 
of drugs was calculated based on acquisition costs for 
drugs used at the index visit, with the quantity of inject-
able drugs being rounded up to the nearest full phial size. 
Investigations performed were costed on charge per test, 
except for those performed as part of clinical research, 
which were excluded. Staff costs for inpatient visits used 
the combined daily salary of all staff present divided by 
the number of beds in the ward, then multiplied by the 
patient’s length of stay in days; staff costs of emergency 
outpatient visits were calculated by dividing the combined 
daily salary of staff by the mean daily number of visits to 
the department. Facility costs were calculated by dividing 
the facility’s mean daily cost for services and subsistence 
goods by the number of hospital beds, then multiplying 
by the patient’s length of stay. The cost of consumable 
goods in the clinic such as tubing for intravenous drips 
was not included. Household costs included transporta-
tion to the index visit for the patient, their main caretaker 
and any other household visitors during admission; direct 
medical costs (costs of consultations, drugs and diagnos-
tics not covered by the essential health package); lost 
income attributable to the episode of disease; and subsis-
tence (food and shelter) during the visit. Lost income was 
calculated by dividing the self-reported monthly income 
group.bmj.com on November 2, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
 3Hendrix N, et al. BMJ Open 2017;7:e017347. doi:10.1136/bmjopen-2017-017347
Open Access
Table 1 Patient characteristics
Rural Urban
TotalInpatient Outpatient Inpatient Outpatient
N (% of total) 22 (4%) 108 (21%) 269 (52%) 120 (23%) 519
Mean Vesikari score 
(SD)
6.0 (2.9) 2.6 (2.2) 11.1 (3.9) 2.0 (3.4) 7.0 (5.5)
Sex: male, not 
recorded(%)
13 (59%), 0 67 (62%), 2 (2%) 159 (59%), 2 (1%) 62 (52%), 1 (1%) 301 (58%), 5 (1%)
Mean age, months 
(SD)
14.0 (12.7) 15.8 (11.3) 13.4 (7.4) 15.8 (11.8) 14.3 (9.3)
Median length of 
stay, days (IQR)
2 (2.5) N/A 3 (2) N/A 3 (2) (inpatients only)
Table 2 Mean (SD) total direct and indirect costs for the episode of illness by geography and treatment setting
Rural Urban
Inpatient Outpatient Inpatient Outpatient
Health system costs $55.04 ($26.82) $8.02 ($2.90) $47.21 ($56.69) $7.18 ($4.05)
Household costs $19.16 ($19.30) $1.81 ($2.58) $25.36 ($20.47) $15.48 ($20.75)
Total costs $76.94 ($32.61) $13.57 ($4.70) $73.78 ($51.39) $23.13 ($21.68)
by the number of days in the month, then multiplying by 
the number of days spent in care taking for this episode 
of illness.
Ongoing costs were assessed at a follow-up visit to the 
patient’s home 6 weeks after facility discharge. Costs 
related to any long-term disability caused by the episode 
were not included among these ongoing costs. Again, 
costs to the health system for further treatment could 
not be ascertained due to other sites’ being outside the 
network of research sites.
All costs were collected in Malawi kwacha and converted 
to US$ based on the mid-market exchange rate per the 
Malawi Reserve Bank on 15 July 2014.
statistical analysis
The study’s minimum sample size of 88 was calculated to 
provide an estimate of household costs with a margin of 
error ≤10% given a coefficient of variation of 0.5.9 16
Income quintiles were calculated based on self-re-
ported monthly income within the sample itself—that 
is to say that a household labelled as belonging in the 
highest income quintile is within the top 20% of house-
hold incomes in this sample. Using one-way analysis of 
variance (ANOVA), we tested for differences among 
income quintiles in mean overall household costs at each 
geographic and treatment setting.
To explore associations proposed in previous research 
between prior treatment and cost, we constructed a gener-
alised linear model of total costs and household costs 
with log link on gamma distributional family, adjusted 
for length of stay, geographic setting and treatment 
setting. We used a Χ2 test to compare the proportion of 
patients with prior/ongoing costs in different settings, 
and a rank-sum test to assess differences in component 
costs between these groups. We also used rank-sum tests 
to assess the significance of differences in total (health 
system plus household) and household cost between 
geographic and treatment settings.
ethics
Ethical approval was provided by the National Health 
Sciences Research Committee, Lilongwe, Malawi (1073), 
and by the Research Ethics Committee of the University 
of Liverpool, UK (000490). Written consent was obtained 
from the parents or guardians of participating children.
results
Participants
A total of 529 individuals participated in this study, 
although 15 were excluded due to incomplete data (see 
table 1). The majority (389) were recruited at QECH 
in Blantyre and the remaining 130 participants were 
recruited at CRH in Karonga. Inpatient cases accounted 
for 69% (269/389) of the cases at QECH while only 17% 
(22/130) of cases in Karonga were admitted, reflecting a 
more serious case mix at a much larger national referral 
level hospital in Blantyre.
Total costs for the episode of illness and costs by payer 
are reported in table 2, sorted by geography and treat-
ment setting. The least expensive visit type was a rural, 
outpatient visit with total costs averaging $13.57; rural, 
inpatient visits were the costliest, averaging $76.94. 
Rank-sum tests confirmed the significance of differences 
in both total and household costs between geographic 
and treatment settings (p<0.001 in all cases). Across all 
settings, the health system bore an average of 76% of the 
costs for each episode of illness.
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Table 3 Mean (SD) costs to health system for index visit by category
Rural Urban
Inpatient Outpatient Inpatient Outpatient
Drugs $4.46 ($3.94) $1.45 ($2.53) $9.40 ($20.29) $1.19 ($2.16)
Labs $5.39 ($1.07) $4.96 ($1.17) $7.60 ($5.21) $4.73 ($3.36)
Staff $17.03 ($10.37) $1.61 ($0) $21.47 ($30.51) $1.26 ($0)
Facilities $28.35 ($17.26) $0 ($0) $8.73 ($12.41) $0 ($0)
Total $55.04 ($26.82) $8.02 ($2.90) $47.21 ($56.69) $7.18 ($4.05)
Table 4 Mean (SD) household costs for an episode of illness
Rural Urban
TotalInpatient Outpatient Inpatient Outpatient
Direct medical expenses 
prior to index visit
$0.21 ($0.72) $0.08 ($0.58) $0.98 ($3.92) $0.71 ($1.55) $0.77 ($3.13)
Direct medical expenses of 
index visit
$8.61 ($9.62) $0.24 ($0.68) $10.69 ($10.66) $5.85 ($10.21) $7.31 ($10.17)
Transportation to and 
subsistence at index visit
$4.38 ($5.28) $0.51 ($0.54) $2.68 ($3.00) $0.45 ($1.91) $2.04 ($2.83)
Lost income due to index 
visit
$4.13 ($9.62) $0.50 ($0.68) $8.06 ($10.66) $6.22 ($10.22) $6.36 ($10.17)
Direct medical expenses 
after index visit
$0.87 ($2.10) $0.38 ($1.66) $0.21 ($2.41) $0.16 ($1.19) $0.26 ($2.02)
Total household costs $19.16 ($19.30) $1.81 ($2.58) $25.36 ($20.47) $15.48 ($20.75) $19.32 ($20.66)
We performed a sensitivity analysis to assess the poten-
tial impact to overall costs at the index visit if the 15 
dropped observations were included. Were these costs 
representative of the 25th percentile of costs, mean 
overall costs would decrease from $39.15 to $38.32; were 
they in the 75th percentile of costs, mean overall costs 
would rise to $39.44. This would result in a 2% decrease 
in total costs, or a 0.6% increase, respectively, compared 
with the weighted average of costs across all visit types.
For inpatient settings, staff and facility costs contribute 
the most to health system costs (see table 3). These two 
categories represent between 60% and 80% of total costs 
across geographic settings. Laboratory investigations 
dominate outpatient costs, representing roughly 60% in 
both urban and rural outpatient settings.
Lost income and direct medical expenses make up the 
majority of household costs for all except rural, outpa-
tient visits, whose costs are dominated by transporta-
tion and lost income (see table 4). Of patients seen at 
the urban facility, 35% had sought treatment prior to 
their index visit, compared with 2% of patients seen at 
the rural facility (p<0.001). On the other hand, 13% of 
patients in Karonga had ongoing costs after the index 
visit, compared with 2% of patients seen at the Blantyre 
site (p<0.001).
Using one-way ANOVA to detect differences in mean 
household expenditure (exclusive of lost income) 
between income quintiles, we found a significant differ-
ence only in urban, inpatient encounters (see figure 1). 
The highest income level in this group (>$79.50 per 
month) had higher expenditures than any other income 
group, with the difference between this group and the 
lowest income group (<$19.32 per month) being espe-
cially noticeable. The ANOVA test showed no significant 
differences for any other combination of geographic and 
treatment settings.
Costs to the households of patients for whom previous 
treatment was sought were 2.04 times higher (p<0.001) 
once adjusted for length of stay, geography and treat-
ment setting; overall costs were 1.25 times higher 
(p=0.016). This difference in overall costs is driven in 
part by spending prior to the index visit, which aver-
aged between $0.92 for rural, outpatient index visits and 
$3.01 for rural, inpatient index visits. A rank-sum test on 
transportation costs by prior treatment status showed 
significantly higher transportation costs for this group 
(p<0.001), suggesting the source of these differences. 
Median monthly income for the group who sought prior 
treatment was higher than the group who did not, at 
$34.09 and $22.73, respectively. A rank-sum test again 
showed a significant difference in both monthly income 
and lost income due to the illness (length of stay was not 
significantly different between the groups). We repeated 
the rank-sum test looking for variation in transportation 
costs during the rainy seasons (November through April) 
of those who received prior treatment, but this test’s 
results were not significant.
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Figure 1 Mean total household cost (not including lost income) of inpatient, urban index visit by income.
dIscussIOn
Even following the introduction of the rotavirus vaccine, 
diarrhoeal disease continues to be a significant burden 
on the world and on low-income countries in particular. 
While deaths among African children due to diarrhoea 
declined 43% between 2000 and 2013,17 the number of 
cases remains high, with one study estimating 3.3 episodes 
of diarrhoea annually per child in Africa.18
This study focused on the economic burden of these 
diseases by combining costs ascertained through both 
interviews and chart review. It found significant house-
hold costs primarily in the inpatient and urban settings 
with lost income and direct medical costs dominating the 
contributing costs. Even rural, outpatient visits can be 
financially problematic, however, if they are frequent, or 
if the family is especially vulnerable. Household costs for 
the episode of illness (excluding lost income) exceeded 
monthly household income in 8% of cases treated inpa-
tient and 3% of cases treated outpatient; including lost 
income, these numbers rise to 17% and 9%, respectively.
Taking into account lost income, mean household costs 
for patients seen in the rural health centre were $19.16 
and $1.81 for inpatient and outpatient treatment, while 
patients seen at the urban hospital had mean household 
costs of $25.36 and $15.48 for inpatient and outpatient 
treatment. The high cost of inpatient treatment in the 
urban setting likely reflects the higher acuity of illness at 
that setting: the mean Vesikari score of study participants 
seen in QECH’s inpatient ward was 11, which indicates 
severe disease. Rural inpatients, by comparison, had a 
mean Vesikari score of 6.
Putting household expenditures in context, 72.2% of 
the Malawian population lives on <$1.25 per person per 
day.19 Even an outpatient visit in a rural setting, then, is 
likely to impose costs exceeding a day’s income for this 
population, while a costlier inpatient visit is likely to 
account for almost 3 weeks’ income. The equivalents for a 
US household would be to face costs of $147 and $3,095, 
respectively.20 It should be noted, though, that in a low-in-
come setting, a much larger percentage of income goes 
to core goods such as food and shelter: as such, it is more 
difficult to offset health-related costs. Having savings 
adequate to cover medical costs is also less common in 
this setting, where, although 76% report saving when 
possible, 90% of households say that they sometimes run 
out of money for basic goods.21 This can bring about debt 
and reduced expenditure on clothing, education, shelter 
and other similar goods.
The results of our study can be compared with several 
other studies of the economic burden of diarrhoeal 
disease in the low-income, sub-Saharan context. An 
analysis of economic data from the Global Multicenter 
Enteric Study found mean household costs of $2.77, 
$6.57 and $4.33 (in 2014 USD) for Gambia, Kenya and 
Mali, respectively, for a representative sample of inpa-
tient and outpatient medical encounters, not including 
lost income.22 A Rwandan study of inpatient admissions 
for childhood gastroenteritis found household costs of 
$66.08 (including lost income) and costs to the medical 
system of $34.83.23 Finally, a study from Ghana found 
costs to the medical system of $5.14 for outpatient visits 
and $122.07 for inpatient visits.8
When costs are analysed by income quintile, mean 
household expenditure by quintile is only significantly 
different in the urban, inpatient setting. This demon-
strates that the poorest segments of Malawian society 
who attend public healthcare facilities generally incur 
the same costs as their wealthier peers in the same 
settings. This finding is supported by other evidence 
from Malawi which found that care-seeking behaviour 
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Figure 2 Log monthly household income versus log costs 
for the episode of illness, not including lost income. The line 
represents episode costs equal to monthly income.
for children with diarrhoea does not vary by income 
level.24
The pattern of identical expenditure across income 
quintiles in most settings means that the poorest house-
holds expose themselves to greater risk of impoverishment 
by seeking treatment (see figure 2). After accounting for 
the costs of the episode of illness, no household in the 
lowest income quintile of our sample was left with more 
than $0.60 of income per day for the month in which the 
illness occurred—well below the government’s definition 
of ‘ultrapoverty’ as $1.74 per household per day.25 Further-
more, the costs of the episode of illness exceeded the 
monthly income of 27% of households in this group. Even 
among the highest income quintile of our sample, 19% of 
households were brought temporarily below the poverty 
line of $2.80 per day by the costs of the episode of illness.
We are left to explain why spending increases with 
income quintile in the urban inpatient setting (see 
figure 1). One explanation may be that price sensitivity 
may play a role in care decisions in the urban inpatient 
setting. If this were the case, the children of poorer 
Malawians may not receive the full extent of care that 
they need due to concerns about the costs associated 
with seeking treatment, even when the treatment itself 
is free. Mean total household costs were the highest for 
this setting, and the patients’ caretakers must balance 
the risks of expenses that they cannot afford with the risk 
that their child’s illness will worsen when they choose to 
seek or not seek care. Lower income families may, ratio-
nally, apply a different threshold for seeking treatment 
than higher income families. Another possibility may 
be a tendency of higher income families to bring more 
visitors or to buy higher cost subsistence goods. In order 
to test this possibility, we ran an ANOVA test on mean 
spending by income quintile on visitors, transportation 
and shelter costs (both together and separately), but did 
not find significant differences. Instead, the same test 
shows significantly increased mean spending on direct 
medical expenses as income quintile increases.
One driver of high overall costs in the urban setting 
at large may be the seeking of prior care. Of patients 
seen in the urban setting, 35% had been seen at a prior 
healthcare facility. Testing the relationship between prior 
care and income quintile using a logistic regression does 
not suggest a significant relationship between the two, 
whether income quintile is represented as a continuous 
or factor variable. Excluding lost wages, household costs 
for cases in which prior care is sought cost twice as much 
as cases in which the index visit is the first encounter 
with the healthcare system during this episode of illness. 
Transportation costs are the likely source of difference, 
suggesting that patients who sought treatment prior to 
the index visit come to the hospital either from farther 
away or more urgently than those for whom the index visit 
was their first visit related to this episode. Transportation 
costs predominate costs accrued prior to the index visit as 
well, accounting for 62%; spending at health centres and 
pharmacies accounted for 13% and 11%, respectively. 
Selection bias likely plays a role as well, as the most seri-
ously ill patients are likely both to be seen multiple times 
and to incur greater overall costs.
The conclusions in this study are limited by its being a 
post hoc, unpowered analysis of data gathered for a cost-ef-
fectiveness study. That is, the sample size of the study was not 
powered to detect differences between treatment settings, 
geography or any of the other characteristics examined in 
our regression analysis. The study’s generalisability may also 
be limited due to the data collection’s having taken place in 
two locations that represent extremes of acuity and popu-
lation density within the Malawian healthcare system. We 
cannot rule out greater geographic variation in financial 
outcomes than our study results suggest.
Future work in this area should focus on the long-
term consequences to the household of financial shock 
associated with an episode of diarrhoeal disease, or with 
repeated diarrhoea due to undernourishment and other 
risk factors. Especially of interest is the long-term loss of 
economic potential due to childhood illness: if a child 
is frequently or severely ill, health-related expenditures, 
including time needed for caretaking, may preclude 
investment in other areas that could improve the finan-
cial situation of a household.
cOnclusIOn
This study has evaluated directly the cost of 514 episodes of 
childhood diarrhoeal disease to both the households and 
health system of Malawi. It found that households bear a 
substantial fraction of the total costs of an episode of illness 
and that there is a considerable risk of impoverishment due 
to severe or repeated episodes of diarrhoeal disease.
The conclusions of this study are broadly applicable 
in the sub-Saharan setting—especially to those countries 
where the rotavirus vaccine is widely used—regardless of 
whether healthcare is provided to the public for free or 
through an insurance programme. In the latter case, only 
direct medical costs to the household would be covered. 
Lost income, transportation and ongoing costs of care 
were all found in this study to impose substantial financial 
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burdens, and this observation would not be changed by 
the use of health insurance.
This study’s findings can be applied to cost-effective-
ness analyses of enteric vaccines and other means of 
preventing the transmission of diarrhoeal disease and can 
be used by healthcare planners to help prioritise inter-
ventions. By providing data on the lost financial opportu-
nity caused by an episode of diarrhoeal disease, this study 
allows for a more precise accounting of how an averted 
episode of diarrhoeal disease should be valued.
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